A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
A Long-Term, Open-label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
2019
Journal of Clinical Psychopharmacology
Preserved Fulltext
Supplementary Table 1. Summary of safety outcomes over 52 weeks for patients with MDD receiving open-label adjunctive brexpiprazole 0.5-3 mg/day Safety population (n=2,938) Incidence of treatment-emergent suicidality,* % (n/N) C-SSRS Suicidal ideation 5.5 (161/2,938) C-SSRS Suicidal behavior 0.2 (7/2,938)
doi:10.1097/jcp.0000000000001034
fatcat:sv7zuyib75ghhfyb7gf7zu6iwe